The earnings call highlighted strong progress in clinical trials for RMC-6236 and RMC-9805, a robust financial position, and future plans for pipeline expansion. However, increased expenses and a delay in the lung cancer trial posed challenges.

Company Guidance

During the Q3 2024 earnings call for Revolution Medicines, the company provided guidance highlighting several key metrics and strategic priorities. Revolution Medicines reported cash and investments totaling $1.55 billion at the end of the third quarter, projecting this will fund operations into 2027. R&D expenses rose to $151.8 million from $107.7 million in the same quarter the previous year, driven by clinical trial costs and personnel expansion, while G&A expenses increased to $24.0 million from $15.5 million. The net loss for the quarter was $156.3 million, compared to $108.4 million in Q3 2023. The company reiterated its full-year 2024 GAAP net loss guidance of $560 to $600 million, including a noncash stock-based compensation expense of $70 to $80 million. Revolution Medicines emphasized its progress with RMC-6236, including the initiation of its first global randomized Phase III study in PDAC and outlined plans for upcoming disclosures and future trials in non-small cell lung cancer.

Substantial Progress with RAS(ON) Inhibitors

Initiated the first global randomized Phase III study for RMC-6236 in metastatic PDAC with compelling progression-free survival (PFS) of 8.5 months and overall survival (OS) of 14.5 months for G12X mutation patients.

RMC-9805 Phase I Study Results

Initial clinical data from the Phase I study showed a 30% objective response rate and an 80% disease control rate for RMC-9805 in PDAC, with a manageable safety profile.

Strong Financial Position

Ended Q3 2024 with $1.55 billion in cash and investments, projected to fund operations into 2027.

Pipeline Expansion and Future Plans

Plans to share updates on RMC-6236 and RMC-6291 for non-small cell lung cancer, aiming to initiate a Phase III study in Q1 2025.

---

Revolution Medicines (RVMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RVMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 14, 2020	2020 (Q1)	- / -0.74	-0.225	-228.89% (-0.52)	―	―
Aug 10, 2020	2020 (Q2)	- / -0.46	-0.232	-98.28% (-0.23)	―	―
Nov 12, 2020	2020 (Q3)	- / -0.42	-0.37	-13.51% (-0.05)	―	―
Mar 02, 2021	2020 (Q4)	- / -0.52	-6.5	92.00% (+5.98)	―	―
May 10, 2021	2021 (Q1)	-0.52 / -0.53	-0.74	28.38% (+0.21)	―	―
Aug 11, 2021	2021 (Q2)	-0.56 / -0.60	-0.46	-30.43% (-0.14)	―	―
Nov 10, 2021	2021 (Q3)	-0.63 / -0.72	-0.42	-71.43% (-0.30)	―	―
Feb 28, 2022	2021 (Q4)	-0.64 / -0.71	-0.52	-36.54% (-0.19)	―	―
May 09, 2022	2022 (Q1)	-0.78 / -0.78	-0.53	-47.17% (-0.25)	―	―
Aug 09, 2022	2022 (Q2)	-0.85 / -0.82	-0.6	-36.67% (-0.22)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

RVMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2024	$59.42	$59.10	-0.54%
Aug 07, 2024	$42.27	$41.98	-0.69%
May 08, 2024	$38.31	$37.45	-2.24%
Feb 26, 2024	$30.38	$30.62	+0.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---